{"id":1131,"date":"2002-10-01T12:04:00","date_gmt":"2002-10-01T10:04:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2002\/inhalatives-iloprost-bei-pulmonaler-hypertonie-die-air-studie"},"modified":"2022-03-17T14:10:12","modified_gmt":"2022-03-17T13:10:12","slug":"inhalatives-iloprost-bei-pulmonaler-hypertonie-die-air-studie","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2002\/inhalatives-iloprost-bei-pulmonaler-hypertonie-die-air-studie","title":{"rendered":"Inhalatives Iloprost bei pulmonaler Hypertonie. Die AIR-Studie"},"content":{"rendered":"<p>Prostazyklin-Infusionen bessern die Symptome und gering auch die Prognose von Patienten mit schwerer pulmonaler Hypertonie (Barst, R.J., et al.: N. Engl. J. Med. 1996, 334, 296). Ein klinisches Problem dieser Therapie ist, da\u00df Prostazykline eine kurze Halbwertszeit haben und durch Magens\u00e4ure inaktiviert werden. Daher mu\u00df die Substanz bislang als Dauerinfusion \u00fcber eine Pumpe und \u00fcber [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Prostazyklin-Infusionen bessern die Symptome und gering auch die Prognose von Patienten mit schwerer pulmonaler Hypertonie (Barst, R.J., et al.: N. Engl. J. Med. 1996, 334, 296). Ein klinisches Problem dieser Therapie ist, da\u00df Prostazykline eine kurze Halbwertszeit haben und durch Magens\u00e4ure inaktiviert werden. Daher mu\u00df die Substanz bislang als Dauerinfusion \u00fcber eine Pumpe und \u00fcber [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[2799,324,325,2800,514],"class_list":["post-1131","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-air-studie","tag-blutdruck","tag-hypertonie","tag-iloprost","tag-pulmonale-hypertonie"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1131","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1131"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1131\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1131"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1131"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1131"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}